Business Context and Reporting Period
Rocket Pharmaceuticals, Inc. (RCKT) filed a Form 8-K on February 24, 2022, to announce its financial results for the quarter and full year ended December 31, 2021. The company is incorporated in Delaware and trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus prior periods. It serves solely as a notification that the results for the period ended December 31, 2021, have been announced.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. The document explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the full-year 2021 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has elected to use the extended transition period for emerging growth companies.